Æó ¸¶Ä¿ ½ÃÀå º¸°í¼­ : ¾Ï À¯Çüº°, ¸¶Ä¿ À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)
Lung Marker Market Report by Cancer Type (Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), Marker Type (EGFR, EML4-ALK, KRAS, BRAF, and Others), End User (Hospitals, Diagnostic Labs, and Others), and Region 2025-2033
»óǰÄÚµå : 1661075
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,339,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,786,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,233,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Æó ¸¶Ä¿ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 4¾ï 8,220¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 11¾ï 460¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025³âºÎÅÍ 2033³â±îÁö 9.6%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

ÀϹÝÀûÀ¸·Î EGFR, EML4-ALK, KRAS, BRAF¸¦ Æ÷ÇÔÇÑ 4°¡Áö ÁÖ¿ä Æó Ç¥½ÄÀÚ´Â Æó ÁßÀç ½Ã¼ú, Æó ¼ö¼ú, Áø´Ü ½Ã »ç¿ëµË´Ï´Ù. ¶ÇÇÑ, ¸¶Ä¿´Â Á¾¾çÀÇ Å½Áö, Áø´Ü, ¿¹Ãø, ¸ð´ÏÅ͸µ¿¡ »ç¿ëµÇ¸ç, À̸¦ ¹ÙÅÁÀ¸·Î ȯÀÚ¿¡°Ô Ä¡·á¹ýÀ» ó¹æÇÕ´Ï´Ù. Æó ¸¶Ä¿´Â ÀϺΠ¿µ»ó °Ë»ç ¹× »ý°Ë°ú ÇÔ²² ¾ÏÀ» ½Äº°Çϱâ À§ÇÑ Ãß°¡ µµ±¸·Î¸¸ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ ÀÌÀ¯·Î Æó ¸¶Ä¿´Â º´¿ø, ¿Ü·¡ ¼ö¼ú Ŭ¸®´Ð, Àü¹® Ŭ¸®´Ð µî ¿©·¯ ÀÇ·á ½Ã¼³¿¡¼­ Èä°­°æ ¼ö¼ú¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

´ë±â¿À¿°ÀÇ Áõ°¡·Î ÀÎÇÑ Èä¼ö, È丷 ÁßÇÇÁ¾, È丷 ÇöóÅ©¿Í °°Àº È£Èí±âÁúȯÀÇ À¯º´·ü Áõ°¡°¡ Æó ¸¶Ä¿ÀÚ ¼ö¿ä Áõ°¡ÀÇ ¹è°æÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿©±â¿¡ ´õÇØ °£Á¢Èí¿¬¿¡ ´ëÇÑ ³ôÀº ³ëÃâ°ú Æó¾ÏÀÇ °¡Á··ÂÀÌ Æó¾Ï ȯÀÚ ¼ö¸¦ ´õ¿í Áõ°¡½ÃÄÑ Æó¾Ï ¸¶Ä¿¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ³ë·É Àα¸ÀÇ ±ÞÁõ°ú ³ôÀº Èí¿¬À²·Î À̾îÁö´Â ¹Ù»Û ¼ÒºñÀÚ ¶óÀÌÇÁ½ºÅ¸ÀÏÀº ÀϺΠȣÈí±âÁúȯÀÇ À§ÇèÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, Æó¾Ï°ú °°Àº »ý¸íÀ» À§ÇùÇÏ´Â Áúº´ÀÇ Á¶±â Áø´Ü ¹× »çÀü Ä¡·á¸¦ À§ÇØ °¢±¹ Á¤ºÎÀÇ ÀÇ·áºñ ÁöÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Àü ¼¼°èÀûÀ¸·Î Æó ¸¶Ä¿ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Æó¾Ï Áø´Ü ¹× Ä¡·á ºÐ¾ßÀÇ ¿©·¯ ¿¬±¸ °³¹ß Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó Æó ¸¶Ä¿¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ º´¿ø, ¼ö¼ú ¼¾ÅÍ, Ŭ¸®´Ð¿¡¼­ Æó ¸¶Ä¿ÀÇ »ç¿ë·® Áõ°¡¿Í Ä¡·á ¸ñÀûÀÇ ´Ù¾çÇÑ ¿ëµµµµ Á¦Ç° ¼ö¿ä¸¦ ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ Æó ¸¶Ä¿ ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : ¾Ï À¯Çüº°

Á¦7Àå ½ÃÀå ³»¿ª : ¸¶Ä¿ À¯Çüº°

Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

Á¦10Àå SWOT ºÐ¼®

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

Á¦13Àå °¡°Ý ÁöÇ¥

Á¦14Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global lung marker market size reached USD 482.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,104.6 Million by 2033, exhibiting a growth rate (CAGR) of 9.6% during 2025-2033.

Generally, four major types of lung markers, including EGFR, EML4-ALK, KRAS, and BRAF, are used during lung intervention procedures or lung surgeries and diagnosis. Furthermore, the markers are used to detect, diagnose, predict, and monitor the tumor, based on which the treatment is prescribed to the patient. Lung markers are only used as an additional tool to identify cancer along with several imaging tests and biopsy. Owing to this, lung markers are extensively used in thoracoscopic surgeries across hospitals, ambulatory surgical clinics, and specialty clinics, among several other healthcare facilities.

The rising demand for lung markers can be attributed to the high prevalence of respiratory disorders, such as pleural effusion, pleural mesothelioma, pleural plaque, etc., due to the increasing air pollution levels, across the globe. Besides this, the high exposure to passive smoking, along with a family history of lung cancer further drives the number of patients suffering from lung cancer, thereby augmenting the demand for lung markers. Additionally, the surging geriatric population, along with the hectic consumer lifestyles leading to a high smoking rate, further accelerate the risks of several respiratory disorders. Apart from this, the increasing healthcare expenditures by various governments for early diagnosis and pre-treatment of life-threatening diseases, such as lung cancer, are also propelling the rising utilization of lung markers at a global level. Furthermore, rising investments in several research and development activities in the field of lung cancer diagnostics and treatment is further catalyzing the demand for lung markers. In addition to this, the increasing usage of lung markers in hospitals, surgery centers, clinics, and their various applications in therapeutic purposes has also catalyzed the product demand.

Key Market Segmentation:

Breakup by Cancer Type:

Breakup by Marker Type:

Breakup by End User:

Breakup by Region:

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Beckman Coulter, Inc., Fujirebio Europe N.V., Hologic, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers, and BioSpace, Inc.

Key Questions Answered in This Report:

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Lung Marker Market

6 Market Breakup by Cancer Type

7 Market Breakup by Marker Type

8 Market Breakup by End User

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Indicators

14 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â